{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T12:19:20Z","timestamp":1787833160029,"version":"build-2784847793"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.therap.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T23:19:49Z","timestamp":1783639189000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute pancreatitis followed by leukocytoclastic vasculitis induced by tirzepatide: A first case report with this new medication"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5849-263X","authenticated-orcid":false,"given":"Fatma","family":"Zgolli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiem","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imen","family":"Aouinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Israa","family":"Dahmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hela","family":"Haouet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Kooli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarrah","family":"Kastalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihem","family":"El Aidli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2026.06.003_bib0075","unstructured":"Eli Lilly, Company. FDA approves Lilly\u2019s Mounjaro\u2122 (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes [news release]. Indianapolis (IN): Eli Lilly and Company; 2022. https:\/\/www.investor.lilly.com. [Accessed 30 June 2026]."},{"key":"10.1016\/j.therap.2026.06.003_bib0080","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.therap.2026.06.003_bib0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2515\/therapie\/2013016","article-title":"Cercle de R\u00e9flexion sur l\u2019Imputabilit\u00e9 (CRI). Updating the French method for the causality assessment of adverse drug reactions","volume":"68","author":"Arimone","year":"2013","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2026.06.003_bib0090","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.therap.2026.06.003_bib0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.therap.2022.03.001","article-title":"Pharmacovigilance and drug safety: fair prescribing and clinical research","volume":"77","author":"Montastruc","year":"2022","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2026.06.003_bib0100","doi-asserted-by":"crossref","first-page":"102489","DOI":"10.1016\/j.cpcardiol.2024.102489","article-title":"Tirzepatide: a novel cardiovascular protective agent in type 2 diabetes mellitus and obesity","volume":"49","author":"Sardar","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.therap.2026.06.003_bib0105","doi-asserted-by":"crossref","first-page":"1214334","DOI":"10.3389\/fendo.2023.1214334","article-title":"Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.therap.2026.06.003_bib0110","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/17512433.2020.1736041","article-title":"Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials","volume":"13","author":"Singh","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.therap.2026.06.003_bib0115","doi-asserted-by":"crossref","first-page":"e70032","DOI":"10.1002\/osp4.70032","article-title":"Pancreatic safety of tirzepatide and its effects on islet cell function: a systematic review and meta-analysis","volume":"10","author":"Kamrul-Hasan","year":"2024","journal-title":"Obes Sci Pract"},{"key":"10.1016\/j.therap.2026.06.003_bib0120","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) EMA\/539700\/2023. Mounjaro-H-C-005620-II-0007: EPAR assessment report\u2013variation. Amsterdam: EMA; 2023.https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/mounjaro-h-c-005620-ii-0007-epar-assessment-report-variation_en.pdf. [Accessed 30 June 2026 (167 pp)]."},{"key":"10.1016\/j.therap.2026.06.003_bib0125","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1080\/03007995.2024.2386047","article-title":"The first report of leukocytoclastic vasculitis induced by once-weekly subcutaneous semaglutide","volume":"40","author":"Pinheiro","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.therap.2026.06.003_bib0130","doi-asserted-by":"crossref","first-page":"s21","DOI":"10.1016\/j.eprac.2022.03.067","article-title":"Abstract #1161775: semaglutide-induced leukocytoclastic vasculitis","volume":"28","author":"Farasat","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.therap.2026.06.003_bib0135","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from the IMPROVE-IT trial","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.therap.2026.06.003_bib0140","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/j.1756-185X.2010.01481.x","article-title":"ANCA-positive vasculitis associated with simvastatin\/ezetimibe: expanding the spectrum of statin-induced autoimmunity?","volume":"13","author":"Sen","year":"2010","journal-title":"Int J Rheum Dis"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595726000752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:36:31Z","timestamp":1787830591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595726000752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":14,"alternative-id":["S0040595726000752"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2026.06.003","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute pancreatitis followed by leukocytoclastic vasculitis induced by tirzepatide: A first case report with this new medication","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}